Key Highlights

  • Argent BioPharma shares touched a 52-week low during the session on Monday 9 November 2026 and closed at $0.019, down 13.64%.
  • On 27 October 2026 Argent signed a 10-year exclusive worldwide licence for four cannabis genotypes with Thai Phytomed International.
  • Argent will receive a 15% Royalty based on profits from commercialisation of the licensed genetics.

Argent BioPharma Ltd (ASX:RGT) touched a 52-week low during the Trading session on Monday, 9 November 2026, and closed at $0.019, down 13.64%. Argent is a biopharmaceutical company focused on immune modulation and anti-inflammatory therapeutics, and it is working to monetise non-core legacy cannabis assets.

Latest Development: Licence Agreement, 27 October 2026

On 27 October 2026, Argent announced a 10-year exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. for the commercial development of four proprietary cannabis genotypes.

Argent keeps ownership of the genetics and related intellectual property. The licensee takes exclusive global rights to cultivation, processing, extraction, Manufacturing and sale, and funds commercialisation and regulatory approvals.

Argent will receive a 15% royalty on profits, including qualifying sublicensing activities.

About the Company

Argent describes the agreement as supporting its strategy of monetising non-core legacy Assets while keeping its internal focus on pharmaceutical development.

Sector Context

Cannabis-derived product markets are subject to changing regulation across countries, which affects the timing and value of licensing deals for genetics and related intellectual property.

Risks and What to Watch Ahead

The royalty depends on the licensee's commercial success and regulatory approvals in each market, which Argent does not control.

Watch items include regulatory progress by the licensee and updates on Argent's pharmaceutical pipeline.

Final Word

Argent's October licence transfers commercial rights for four cannabis genotypes in exchange for a royalty, with Argent keeping ownership of the underlying genetics.